JP2011236144A - Composition for oral cavity, and foul-breath inhibitor - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a composition for the oral cavity, having high isovaleric acid production-inhibitory ability, excellent in foul-breath inhibitory effect, also good in preparation stability and feeling in use, thus suitable for foul-breath inhibition, and to provide a foul-breath inhibitor included in the composition.SOLUTION: The composition for the oral cavity is provided, being characterized in obtaining by compounding together (A) moutan root bark extract, (B) p-cymene, and (C) a nonionic surfactant. The foul-breath inhibitor comprises: (A) the moutan root bark extract; (B) p-cymene; and (C) the nonionic surfactant.

Description

  The present invention relates to a composition for oral cavity and a bad breath suppressant having an excellent bad breath suppression effect based on the ability to inhibit isovaleric acid production using a plant extract.

  Bad breath is caused by about 80% of the cause in the oral cavity, and is an unpleasant odor produced by some anaerobic bacteria among hundreds of kinds of bacteria living in the oral cavity. Bacteria belonging to the genus Fusobacterium which have been conventionally studied as representative halitosis producing bacteria metabolize the sulfur-containing amino acid L-methionine to generate methyl mercaptan, which is a typical halitosis component.

  The methyl mercaptan is one of volatile sulfur compounds (hereinafter abbreviated as VSC), and exhibits a cabbage rot-like odor and is one of malodorous substances having a low odor threshold. In addition to methyl mercaptan, VSCs contained in bad breath are known to be hydrogen sulfide and dimethyl sulfide generated by metabolism of sulfur-containing amino acid L-cysteine by bad breath producing bacteria. It is said to be the main ingredient related to the strength of

  However, when the actual bad breath is evaluated, even though VSC is not detected, sensory evaluation senses bad breath, or it is different from VSC alone or a combination of VSC, and the unpleasant odor that sticks to the back of the nose is sensory. Therefore, elucidation of components other than VSC affecting the bad breath and the solution of the odor are desired.

Conventionally, the presence of other odorous components such as volatile lower fatty acids and amines as components other than VSC has been suggested for bad breath (Non-patent Document 1).
However, these components other than VSC were only detected from saliva in the oral cavity, gingival crevicular fluid, or the headspace of the saliva culture solution, and the presence in actual bad breath and its involvement in bad breath were sufficiently Since it has not been verified, it has not been recognized by experts and academic societies as a bad breath component.

  Therefore, the applicant collects the actual breath of human beings, quantifies the amount of isovaleric acid, and evaluates bad breath by actual sensory, so that isovaleric acid, which is a volatile lower fatty acid, becomes bad breath. It was verified that it is present in (mouth) and has an effect on bad breath as a bad breath component (Non-patent Document 2). Isovaleric acid has a very low odor threshold (0.078 ppb), similar to the odor threshold (0.07 ppb) of methyl mercaptan, and has a very small amount of unpleasant odor (Non-patent Document 3). As a result of sensory evaluation of isovaleric acid at a concentration actually detected from bad breath, it was an unpleasant odor. Furthermore, as a result of preparing an odor by combining methyl mercaptan and isovaleric acid and performing sensory evaluation, it was an unpleasant odor that sticks to the back of the nose, different from each odor component alone, It was confirmed that the odor was the same as when evaluated in. Therefore, in order to solve the bad breath derived from isovaleric acid as an odor component other than the bad breath derived from the methyl malcaptan, the conventional bad breath component, a material having an ability to inhibit isovaleric acid production was searched.

  As a method for coping with bad breath, a method using a chemical substance or a plant extract having a high deodorizing effect on VSC such as methyl mercaptan is known (Patent Document 1). An extract is one example (Patent Document 2). However, in these techniques, it is not mentioned at all that the button pi extract is effective in inhibiting the production of isovaleric acid that affects bad breath and has not been known so far.

JP-A-57-204378 Special table 2004-520304 gazette

J. et al. Periodontol, 63 (9), p. 768-775, 1992. 58th Annual Meeting of Japanese Society for Oral Hygiene, General Meeting 59 (4), p. 386, p. 390, 2009. Olfactory and odorous substances 2nd edition (co-authored by Michiaki Kawasaki and Tetsuro Horiuchi, published by Association for Odor Control Research, p. 9, 2000.)

  The present invention has been made in view of the above circumstances, has an ability to inhibit isovaleric acid production, exhibits an excellent halitosis suppression effect, and further has an excellent oral cavity composition and halitosis suppressant having a good formulation stability and usability. The purpose is to provide.

As a result of intensive studies to achieve the above object, the present inventors have excellent isovaleric acid production inhibitory effect by using together (A) button pi (peony skin) extract and (B) p-cymene. It was found that a preparation using a plant extract was obtained, and bad breath derived from isovaleric acid can be effectively suppressed. Furthermore, by combining (A) button pi extract and (B) p-cymene in combination and (C) nonionic surfactant, these act synergistically and have a high isovaleric acid production inhibitory effect. It has been found that a formulation that exhibits excellent halitosis and exhibits excellent stability and usability can be obtained.
It is known that the button pi extract has a deodorizing effect on VSC such as methyl mercaptan and has a bad breath suppressing effect, but the fragrance component p-cymene is combined with the button pi extract, and further a nonionic surfactant is added. The present inventors have newly found that when used together, a high ability to inhibit isovaleric acid production is exhibited, and an excellent halitosis suppression effect based on this is exhibited. In the present invention, the production of isovaleric acid that is present in bad breath (or breath) and affects bad breath can be inhibited, and the bad breath derived from isovaleric acid can be effectively suppressed. Therefore, in the bad breath derived from VSC such as methyl mercaptan. In addition, bad breath derived from isovaleric acid can be suppressed, and thus a high bad breath suppression effect can be expected.

Accordingly, the present invention provides the following oral composition.
Claim 1;
An oral composition comprising (A) a button pi extract, (B) p-cymene, and (C) a nonionic surfactant.
Claim 2;
(C) The oral composition according to claim 1, wherein the nonionic surfactant is polyoxyethylene alkyl ether and / or polyoxyethylene hydrogenated castor oil.
Claim 3;
(A) The composition for oral cavity according to claim 1 or 2, wherein the button pi extract is an ethanol extract of button root bark.
Claim 4;
The composition for oral cavity according to claim 1, 2 or 3, wherein (A) component is blended in an amount of 0.0005 to 0.1% by mass in terms of solids concentration, and (B) component is blended in an amount of 0.001 to 0.1% by mass. object.
Claim 5;
The composition for oral cavity according to any one of claims 1 to 4, which is used for suppressing bad breath.
Claim 6;
A bad breath inhibitor comprising (A) button pi extract, (B) p-cymene, and (C) a nonionic surfactant.

  According to the present invention, it has an excellent ability to inhibit isovaleric acid production, is excellent in halitosis suppression effect, and further has good formulation stability and usability, and is suitable for oral malodor control and oral malodor control. Agent can be provided.

  The present invention will be described in further detail below. The present invention is characterized in that (A) button pi extract and (B) p-cymene are used in combination.

(A) The button pi extract is an extract extracted from the root bark of a button family button (peony), and contains ingredients such as paeonol and paeoniflorin.
The button (peony) is also called as “Otsukagusa”, “Shimogususa” or “Natorigusa”, and its scientific name is “Paeonia suffritusosa Andrews” (Paeonia moutan Sims). The root bark of buttons has long been regarded as a Chinese medicine as “peony skin”, and it has been used as a key medicine to cure gout and headaches, dispel the bloody blood, and circulate the blood vessels.

As a method for extracting the root bark of the button, extraction with a hydrophilic solvent such as ethanol or methanol or a mixed solvent thereof is preferable, and ethanol extraction is more preferable. The solvent used for ethanol extraction may be ethanol alone or hydrous ethanol.
Specifically, a commercially available product can be used as the button pi extract, such as a button pi extract manufactured by Maruzen Pharmaceutical Co., Ltd.

  (B) p-cymene is also called paracymene, paracymene, or isopropylmethylbenzene, and is contained in natural essential oils. p-cymene is particularly abundant in thyme oil (p-cymene content of about 40% by mass). In addition to thyme, each essential oil such as cumin, bold leaf, oregano, ajowan, cascarilla, dill, black pepper, angelica, etc. It is known that 10 mass% or more is contained.

  p-cymene can be used as a single product or as the above essential oil containing p-cymene, such as thyme oil. Specifically, commercially available products such as p-cymene manufactured by Takasago International Inc. and thyme white oil manufactured by Ve Manfis Fragrance Co., Ltd. can be used as thyme oil.

In the present invention, the components (A) and (B) are combined and blended as an isovaleric acid production inhibitor.
In this case, the blending ratio of (A) button pi extract and (B) p-cymene is not particularly limited, but (A) the blend ratio of button solid extract and (B) p-cymene ((B ) / (A)) is preferably in the range of 0.02 to 40, particularly 0.4 to 20 in terms of mass ratio. If the blending ratio is less than 0.02, a sufficient bad breath suppressing effect may not be exhibited, and if it exceeds 40, the feeling of use of the composition such as irritating taste during use may be affected.

(A) The blending amount of the button pie extract is 0.0005 to 0.005 of the whole oral composition in terms of solid concentration of the button pi extract in terms of isovaleric acid production inhibitory effect, bad breath suppressing effect, and formulation stability. 1% (mass%, the same applies hereinafter), particularly 0.001 to 0.05% is preferable. If the blending amount is less than 0.0005%, the effect of inhibiting the production of isovaleric acid may not be sufficiently obtained, and the bad breath suppressing effect may be inferior, and if it exceeds 0.1%, problems may occur in the stability of the preparation. is there.
The solid concentration of the button pi extract is a value of the total amount of the button pi solid obtained by removing the solvent from the extract (button pi extract component + solvent).

  (B) The compounding quantity of p-cymene is 0.001-0.1% of the whole composition, especially 0.005-0.02 at the point of isovaleric acid production inhibitory effect, bad breath suppression effect, and formulation stability. % Is preferred. If the blending amount is less than 0.001%, the isovaleric acid production inhibitory effect is not sufficiently exerted and the bad breath suppressing effect may be inferior, and if it exceeds 0.1%, the stability of the preparation may be impaired. .

  In the present invention, in addition to (A) button pi extract and (B) p-cymene, (C) a nonionic surfactant is used in combination, thereby providing an isovaleric acid production inhibitory effect and a bad breath suppression effect. It can be improved, and the stability and usability of the preparation can be improved.

Nonionic surfactants include polyoxyethylene alkyl ethers, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid esters, decaglycerin monofatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, alkyls, and the like because of their versatility. One type or two or more types such as roll amide are preferably used.
Specifically, polyoxyethylene alkyl ether having 14 to 18 carbon atoms in the alkyl chain, 15 to 30 ethylene oxide average addition moles, polyoxyethylene hydrogenated castor oil having 40 to 100 ethylene oxide average addition moles, Decaglycerin monofatty acid ester having 12 to 18 carbon atoms of fatty acid, sucrose fatty acid ester having 12 to 18 carbon atoms of fatty acid, polyoxygen having 16 to 18 carbon atoms of fatty acid and 10 to 40 ethylene oxide average added mole number Oxyethylene sorbitan fatty acid ester, sorbitan fatty acid ester having 12 to 18 carbon atoms in fatty acid, alkylolamide having 12 to 14 carbon atoms in the alkyl chain, and the like can be used. Among these nonionic surfactants, in particular, polyoxyethylene alkyl ether (alkyl chain having 14 to 18 carbon atoms, ethylene oxide average addition mole number of 15 to 30), polyoxyethylene hydrogenated castor oil (ethylene oxide average addition mole) A number of 40 to 100) is preferably used.

  For example, Nikko Chemical's NIKKOL BC series, NIKKOL BS series, Emulex 100 series, Emarex 600 series made by Nihon Emulsion Co., Ltd. are used as polyoxyethylene alkyl ethers, and Nikko Chemicals Co., Ltd. is used as polyoxyethylene hydrogenated castor oil. Nikkol HCO manufactured by Nihon Emulsion, UNIOX HC manufactured by Nippon Oil & Fats Co., Ltd. are available as NIKKOL TS series, NIKKOL TO series manufactured by Nikko Chemicals, Japan, etc. as polyoxyethylene sorbitan fatty acid esters Emulex ET series manufactured by Emulsion, etc., as decaglycerin mono fatty acid ester, NIKKO Decagln series manufactured by Nikko Chemicals, Ryoto (registered trademark) polyglycester D series manufactured by Mitsubishi Chemical Foods, etc. Yoto (TM) Sugar esters, Dai-ichi Kogyo Seiyaku Co., Ltd. DK ester has been commercialized, it is possible to use these commercially available products.

  (C) The nonionic surfactant is preferably added in an amount of 0.05 to 3%, particularly 0.2 to 2%, based on the stability of the preparation, the bad breath suppressing effect and the feeling of use. If the blending amount is less than 0.05%, sufficient formulation stability may not be obtained, or the bad breath suppression effect due to the combination of poorly water-soluble button pi extract and p-cymene may not be sufficiently exhibited, and the active ingredient may not be There may be a decrease in the feeling of use due to precipitation. If the blending amount exceeds 3%, a feeling of use due to the nonionic surfactant may be reduced.

There is no restriction | limiting in particular as a form of the composition for oral cavity of this invention, According to the objective, it can select suitably, For example, liquids, liquids, such as a solution, emulsion, suspension, gel, cream, ointment, paste Any form, such as a semi-solid, may be used. Moreover, it can be set as a coating agent, a massage agent, a brushing agent, a patch, a spray agent etc. as a usage form.
The composition for oral cavity can be prepared into various preparations such as toothpastes such as toothpaste, liquid toothpaste, liquid toothpaste and moisturized toothpaste, mouthwash, mouthwash, and gum massage cream.

There is no restriction | limiting in particular as a manufacturing method of composition for oral cavity, According to the objective and dosage form, a conventional method can be selected suitably.
The composition of the present invention may further contain other optional components in addition to the above components, depending on the purpose and dosage form of the composition. Specifically, in the case of dentifrice, surfactant other than (C) component nonionic surfactant, abrasive, thickener, binder, sweetener, preservative, organic acid, (A) component An active ingredient other than the above, a fragrance other than the component (B), a colorant, and the like can be used in a normal amount within a range not impairing the effects of the present invention.

Any surfactant can be used without particular limitation as long as it is usually blended in a composition for oral cavity, and examples thereof include an anionic surfactant, a cationic surfactant, and an amphoteric surfactant.
As the anionic surfactant, N-acylamino acid salts, α-olefin sulfonates, alkyl sulfates and the like are preferably used particularly from the viewpoint of versatility. Specifically, sodium lauroyl sarcosine, sodium α-olefin sulfonate having a carbon chain length of 10 to 16 carbon atoms, sodium lauryl sulfate, or the like can be used. Examples of amphoteric surfactants include betaine acetate-type amphoteric surfactants such as alkyldimethylaminoacetic acid betaines and fatty acid amidopropyldimethylaminoacetic acid betaines, and imidazoline types such as N-fatty acid acyl-N-carboxymethyl-N-hydroxyethylethylenediamine salts. Amphoteric surfactants, amino acid type surfactants such as N-fatty acid acyl-L-alginate salts, alkyldimethylamine oxide, and the like can be used.

Examples of the cationic surfactant include a long-chain alkyl short-chain trialkylammonium salt, a long-chain dialkyl short-chain dialkylammonium salt, an alkylpyridinium salt, a benzyl long-chain alkyl short-chain dialkylammonium salt, and derivatives thereof. Specific examples include lauryltrimethylammonium chloride, myristyltrimethylammonium chloride, palmityltrimethylammonium chloride, distearyldimethylammonium chloride, stearyltrimethylammonium chloride, myristylpyridinium chloride, cetylpyridinium chloride, stearylpyridinium chloride and the like. Examples of benzyl long-chain alkyl short-chain dialkylammonium salts and derivatives thereof include benzalkonium chloride and benzethonium chloride.
The blending amount of the surfactant is desirably in a range in which the total amount including the nonionic surfactant (C) is 0.05 to 5% of the entire composition.

Examples of the abrasive include silica-based abrasives such as precipitated silica, silica gel, aluminosilicate, zirconosilicate, dicalcium phosphate dihydrate and anhydrous, calcium pyrophosphate, calcium carbonate, aluminum hydroxide, alumina, Examples thereof include magnesium carbonate, tribasic magnesium phosphate, zeolite, zirconium silicate, and synthetic resin abrasive. These may be used individually by 1 type and may use 2 or more types together.
The content of the abrasive is not particularly limited and can be appropriately selected according to the purpose. However, it is preferably 2 to 40%, particularly 10 to 30% of the entire composition.

Examples of the thickener include glycerin, sorbit, propylene glycol, polyethylene glycol 200 to 20000, polyhydric alcohols such as xylitol, and sugar alcohols. These may be used individually by 1 type and may use 2 or more types together.
There is no restriction | limiting in particular in content of a viscous agent, Although it can select suitably according to the objective, 5 to 50% of the whole composition, especially 20 to 45% are preferable.

Examples of the binder include sodium carboxymethyl cellulose, hydroxyethyl cellulose, carrageenan, sodium alginate, xanthan gum, sodium polyacrylate, carbopol, guar gum, montmorillonite, gelatin and the like. These may be used individually by 1 type and may use 2 or more types together.
There is no restriction | limiting in particular in content of a binder, According to a dosage form, it can select suitably. For example, in the case of toothpaste, 0.1 to 5% of the entire composition is preferable, and in the case of liquid dosage forms such as liquid toothpaste and mouthwash, 0.01 to 5% is preferable.

  Examples of sweeteners include saccharin sodium, erythritol, xylitol, lactitol, maltitol, mannitol, palatinose, reduced palatinose (palatinite), raffinose, melibiose, thaumatin, aspartame, acesulfame K, cyclamate sodium, stevioside, stevia extract, paramethoxy Cinnamic aldehyde, neohesperidyl dihydrochalcone, perillaltine, p-methoxycinnamic aldehyde, trehalose, palatinose, palatinit, soybean oligosaccharide, dairy oligosaccharide, xylooligosaccharide, L-aspartyl-L-phenylalanine methyl ester, sucralose, glycyrrhizin Etc. Examples of the preservative include paraoxybenzoic acid ester, benzoic acid, benzoate and the like. These components can be blended in a usual amount as long as the effects of the present invention are not hindered.

  As the organic acid, various organic acids that can be generally used for oral compositions can be used. For example, citric acid, isocitric acid, malic acid, acetic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, maleic acid, fumaric acid, aconitic acid, lactic acid, tartaric acid, pyruvic acid, ascorbic acid, glycolic acid or salts thereof One type or two or more types are used. Among organic acids, citric acid, malic acid, tartaric acid, lactic acid, or salts thereof are particularly preferable.

As an active ingredient, for example, sodium fluoride, sodium monofluorophosphate, tin fluoride, sodium azulenesulfonate, ε-aminocaproic acid, allantoin, allantoinchlorohydroxyaluminum, allantoindihydroxyaluminum, epidihydrocholesterin, dihydrocholesterol, Sodium chloride, glycyrrhizic acid, diammonium glycyrrhizinate, disodium glycyrrhizinate, trisodium glycyrrhizinate, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, β-glycyrrhetinic acid, isopropylmethylphenol, cetylpyridinium chloride, decalinium chloride, benzalco chloride Ni, Benzethonium chloride, Alkyldiaminoethylglycine hydrochloride, Chlorhexidine hydrochloride, Tri Closan, ascorbic acid, sodium ascorbate, pyridoxine hydrochloride, dl-α-tocopherol acetate, dl-α-tocopherol nicotinate, zeolite, disodium dihydrogen pyrophosphate, sodium pyrophosphate, anhydrous sodium pyrophosphate, sodium monohydrogen phosphate , Trisodium phosphate, sodium polyphosphate, calcium glycerophosphate, lysozyme chloride, copper chlorophyllin sodium, copper gluconate, zinc gluconate, zinc chloride, hinokitiol, tranexamic acid, dextranase, aluminum lactate, potassium nitrate, protease, etc. .
The content of the active ingredient can be an effective amount as long as the effect of the present invention is not hindered, but is usually 0.001 to 5% of the entire composition.

  As the fragrance, in addition to the p-cymene of the component (C), for example, natural fragrances, single fragrances, blended fragrances, etc., known fragrance materials used for oral compositions may be used alone or in combination of two or more. Can do. Content of a fragrance | flavor can be made into a normal amount in the range which does not prevent the effect of this invention.

  EXAMPLES Hereinafter, although an experiment example, an Example, and a comparative example are given and this invention is demonstrated more concretely, this invention is not limited to the following Example. In the following examples,% is mass%.

In the following example, a button pi extract manufactured by Maruzen Pharmaceutical Co., Ltd. was used as the button pi extract. The product composition used is composed of 2.00% of a solid substance obtained by extracting the root bark of a button family plant button, 49.00% ethanol, and 49.00% water.
Also, pomegranate peel extract (80% solids) is manufactured by Kikkoman Co., lutein is a dietary marigold pigment preparation manufactured by Kemin Health, crocetin is dietary gardenia yellow pigment manufactured by Riken Vitamin Co., and thyme oil is Toyoda Flavor Co., Ltd. Thyme oil (containing 30% p-cymene), p-cymene, 1,2-pentanediol, p-methoxyphenol are manufactured by Wako Pure Chemical Industries, Ltd., farnesol is manufactured by Kanto Chemical Co., polyoxyethylene (60) cured Castor oil (ethylene oxide (EO) average addition mole number 60) is HCO-60 manufactured by Nikko Chemicals, and polyoxyethylene lauryl ether (EO average addition mole number 25) is EMALEX 725 manufactured by Nippon Emulsion Co., myristic acid diethanolamide. Is Toho N-230X manufactured by Toho Chemical Co., Ltd. Lil Nikko Chemicals Co. NIKKOL Decaglyn 1-L, sucrose fatty acid esters are manufactured by Mitsubishi Chemical Foods the Ryoto Sugar Ester L-1695, were used, respectively.

[Experimental example]
About the sample formulation of the composition shown to Tables 1-4, the isovaleric acid production inhibition test was implemented as follows. The results are shown in Tables 1-4.

Isovaleric acid production inhibition test:
(1) Strain used Porphyromonas gingivalis (Porphyromonas gingivalis ATCC33277) purchased from American Type Culture Collection was cultured at 8,000 rpm for 24 hours in a medium (Todd Hewitt Broth (BD)) supplemented with hemin and menadione. The cells were collected by centrifugation for 10 minutes, washed twice with PBS (phosphate buffered saline: manufactured by Wako Pure Chemical Industries, Ltd.), and then resuspended in the sterilized medium shown below.

(2) Reaction conditions Isovaleric acid production system:
The sterile medium includes Tryptic Soy Broth; TSB (BD) final concentration 1.5%, yeast extract (BD) final concentration 0.25%, hemin (manufactured by Wako Pure Chemical Industries, Ltd.) final concentration 2.5 μg / mL, menadione (Wako Pure Chemical Industries, Ltd.) What was prepared so that it might become final concentration of 0.5 microgram / mL was used. A branched amino acid (L-leucine; manufactured by Wako Pure Chemical Industries, Ltd.) and α-ketoglutaric acid (manufactured by Wako Pure Chemical Industries, Ltd.) serving as a substrate for isovaleric acid are dissolved and prepared (pH 7.0) in PBS. It added to the above-mentioned sterilized medium so that it might become 2.5 mM each. The sterilized medium was sterilized by an autoclave, and the substrate solution was sterilized by a 0.22 μm filter (Millipore). To this, the P.I. The gingivalis bacterial solution was added so that the turbidity at 550 nm was 1.0 at the final concentration of the reaction solution.
The reaction solution was cultured for 18 hours under anaerobic conditions, and the supernatant after centrifugation at 12,000 rpm for 5 minutes was filtered through a 0.45 μm filter (manufactured by Kanto Chemical Co., Inc.). 1 mL of this was extracted with 1 mL of ethyl acetate under sulfuric acid acidity, dehydrated with sodium sulfate, and then 5 μL of the ethyl acetate phase was subjected to gas chromatography analysis to quantitate isovaleric acid. The gas chromatography conditions are shown below.

(3) Evaluation of isovaleric acid production inhibitory effect of test sample The samples (aqueous solution or ethanol solution) described in Tables 1 to 4 were added to the isovaleric acid production system, and the reaction was similarly performed under anaerobic conditions for 18 hours. I let you. In the sample, each component was added so that the final concentration was the concentration shown in the table.
From the average of the results of measuring the amount of isovaleric acid by gas chromatography under the following conditions, the rate of inhibition of isovaleric acid production was calculated using the following formula and evaluated according to the following criteria.
In addition, the result of the conditions in which only the substrate and the bacterial solution were cultured was used as a control.
Isovaleric acid production inhibition rate (%) = [(C−S) / C] × 100
C: control amount of isovaleric acid S: amount of isovaleric acid when the test solution (sample) was added

Criteria for isovaleric acid production inhibitory effect;
◎: Isovaleric acid production inhibition rate of 70% or more ○: Isovaleric acid production inhibition rate of 50% or more and less than 70% Δ: Isovaleric acid production inhibition rate of 30% or more and less than 50% ×: Isovaleric acid production inhibition rate of less than 30%

Gas chromatography measurement conditions;
Device: GC14BPF (manufactured by Shimadzu Corporation)
Column: FFAP + H ₃ PO ₄ (0.3 + 0.3%) Graphite Carbon 60/80 1.6 mm × 3.2 mm glass packed column Column temperature 130 ° C. Temperature rise 16 ° C./min. 210 ° C., 10 min. Holding Inlet temperature 230 ° C
Carrier gas: N ₂ 50 mL / min.
Detector: FID (230 ° C)

  From the results shown in Tables 1 to 3, when the button pi extract or p-cymene was added alone, it did not show a satisfactory isovaleric acid production inhibitory effect. It was revealed that isovaleric acid produced by gingivalis is synergistically inhibited.

  From the results in Table 4, the pomegranate peel extract, lutein, crocetin, 1,2-pentanediol, p-methoxyphenol, and farnesol have the isovaleric acid production inhibitory effect alone, respectively, with the button pi extract or p-cymene. Although it is the same level, even when these components are combined with the bouncypi extract or p-cymene, no high isovaleric acid production inhibitory effect is exhibited in any case, and the synergistic effect of both components is not recognized. Thus, it has been clarified that the isovaleric acid production inhibitor effect obtained in the present invention is an effect manifested only in the combined use of button pi extract and p-cymene.

[Examples 1-13, Comparative Examples 1-6]
Hereinafter, formulation examples relating to the composition for oral cavity of the present invention will be shown. In addition, the compounding quantity of the button pi extract also showed the solid substance conversion amount.

  In addition, mouthwash compositions having the compositions shown in Tables 5 and 6 were prepared by the following method and injected into a polyethylene terephthalate (PET) container. Preparations are prepared by dissolving water-soluble raw materials (excluding nonionic surfactants and solvents) in purified water according to the composition in the table, and then dissolving the oil-soluble raw materials and nonionic surfactants in ethanol or polyhydric alcohol. The mixture was added with stirring and dissolved uniformly. A three-one motor (BL1200, manufactured by HEIDON) was used for stirring.

The isovaleric acid production inhibitory effect of the composition was evaluated by the same methods and criteria as described above, and the preparation stability, feeling of use, and bad breath suppression effect were evaluated by the methods and criteria described below.
(1) Evaluation Method of Formulation Stability Formulation stability was evaluated based on the following criteria by visually judging the appearance after storage for 1 month at 50 ° C. after preparation of the formulation.
Evaluation criteria for formulation stability ◎: No turbidity ○: Yes, almost no turbidity △: Yes, some turbidity ×: Yes, some turbidity

(2) Evaluation method of feeling of use The sensory evaluation by five persons in charge was performed by using the irritation after 20 mL of the preparation was rinsed for 30 seconds as an index of feeling of use. In addition, formulation evaluation was implemented at intervals of 30 minutes or more.
Evaluation criteria for feeling of use (evaluator's score)
4 points: Stimulation is not felt and usability is good 3 points: Stimulus is hardly felt and usability is quite good 2 points: Stimulation is felt slightly and usability is slightly bad 1 point: Stimulation is felt and usability is poor Evaluation criteria for use feeling (average value of 5 evaluators)
◎: 3.5 points or more ○: 3.0 points or more and less than 3.5 points △: 2.0 points or more and less than 3.0 points ×: Less than 2.0 points

(3) Evaluation method of halitosis suppression effect:
After the mouth was closed for 3 minutes, it was collected in a 200 mL tedra bag (Omi Odo Air Service Co., Ltd.), and then sensory evaluation (based on 6-step odor intensity display method) was conducted by two specialist panels. Was calculated. Judgment was carried out according to the bad breath judgment criteria shown below.
6-step odor intensity display method (conformity)
0 point: Odorless 1 point: Smell that can finally be sensed
2 points: A weak scent that can tell you what kind of smell (slightly unpleasant odor)
3 points: Smell that can be easily detected 4 points: Strong odor 5 points: Strong odor Criteria for bad odor Average odor intensity ◎: 1 point or less ○: 1 point and less than 2 △: 2 points or more and less than 3 ×: 3 or more

  When the following oral compositions were prepared and evaluated in the same manner as described above, they were all excellent in isovaleric acid acidity inhibiting effect and bad breath inhibiting effect, and the appearance stability and usability of the preparation were also good. In addition, p-cymene is not contained in the fragrance | flavor mix | blended in the following example.

[Example 14] Toothpaste button pi extract (solids concentration 2%) 1.0%
(Solid matter concentration 0.02%)
p-cymene 0.02
Precipitating silica (abrasive) 25.0
Glycerin (viscous agent) 25.0
Sorbit 15.0
Xylitol (Thickener, sweetener) 10.0
Polyoxyethylene lauryl ether (EO average addition mole number 25) 1.0
Myristic acid diethanolamide 2.0
Fragrance 1.0
Saccharin sodium (sweetener) 0.2
Purified water balance
Total 100.0%
p-cymene / buttonpi extract solids concentration ratio = 1

[Example 15] Liquid dentifrice button pi extract (solids concentration 2%) 0.5%
(Solid matter equivalent amount 0.01%)
p-cymene 0.01%
Aluminum hydroxide (abrasive) 25.0
Glycerin (viscous agent) 40.0
Sorbit 15.0
Carboxymethyl cellulose (degree of polymerization = 500) (binding agent) 0.2
Propylene glycol (viscosity agent) 2.0
Sodium lauryl sulfate 1.5
Decaglyceryl monolaurate 1.0
Polyoxyethylene hydrogenated castor oil (EO average added mole number 60) 1.0
Fragrance 1.0
Saccharin sodium (sweetener) 0.1
Natto fungus gum 0.1
Purified water balance
Total 100.0%
p-cymene / buttonpi extract solids concentration ratio = 1

Example 16 Mouthwash button pi extract (solids concentration 2%) 0.5%
(Solid matter equivalent amount 0.01%)
Thyme oil (p-cymene content 30%) 0.02
(P-cymene conversion concentration 0.006%)
Ethanol 20.0
Fragrance 1.0
Polyoxyethylene hydrogenated castor oil (EO average added mole number 60) 0.3
Sodium monofluorophosphate 0.1
Saccharin sodium 0.05
Isopropyl methylphenol 0.05
Purified water balance
Total 100.0%
p-cymene / buttonpi extract solids concentration ratio = 0.6

[Example 17] Mouth freshener button paste extract (solids concentration 2%) 0.5
(Solid matter equivalent amount 0.01%)
p-cymene 0.01
Ethanol 30.0
Glycerin 15.0
Saccharin sodium 0.3
Sucrose fatty acid ester 3.0
Fragrance 1.0
Purified water balance
Total 100.0%
p-cymene / buttonpi extract solids concentration ratio = 1

Claims (6)

  An oral composition comprising (A) a button pi extract, (B) p-cymene, and (C) a nonionic surfactant.   (C) The oral composition according to claim 1, wherein the nonionic surfactant is polyoxyethylene alkyl ether and / or polyoxyethylene hydrogenated castor oil.   (A) The composition for oral cavity according to claim 1 or 2, wherein the button pi extract is an ethanol extract of button root bark.   The composition for oral cavity according to claim 1, 2 or 3, wherein (A) component is blended in an amount of 0.0005 to 0.1% by mass in terms of solids concentration, and (B) component is blended in an amount of 0.001 to 0.1% by mass. object.   The composition for oral cavity according to any one of claims 1 to 4, which is used for suppressing bad breath.   A bad breath inhibitor comprising (A) button pi extract, (B) p-cymene, and (C) a nonionic surfactant.